PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
August 26 2021 - 6:00AM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled
aspirin capsules (referred to together as “VAZALORE”), today
announced that VAZALORE is now on shelves at major retailers and
e-commerce sites nationwide. A national television campaign will
also kick-off today and feature spots on high-visibility sports
programming as well as popular cable networks.
“We are excited that VAZALORE has hit the shelves nationally and
look forward to communicating the benefits of this innovative
aspirin therapy to millions of patients at risk for vascular
disease,” stated Natasha Giordano, Chief Executive Officer of PLx.
“We are confident consumers will recognize VAZALORE as a
breakthrough in aspirin delivery, designed to help protect the
stomach while providing all of the benefits of aspirin to help
prevent another heart attack or clot-related stroke.”
VAZALORE, the first and only U.S. Food and Drug Administration
(“FDA”) approved liquid-filled aspirin capsules, is available in
VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count and VAZALORE 325
mg, 30 count.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
ContactInvestor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
A photo accompanying this announcement is available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8d9940c-c2da-487f-b090-acaada2dbcdc
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024